Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients

Inclusion Criteria

• •Advanced myeloma, with measurable disease as defined in the protocol.
• •Prior treatment, at least 2 prior regimens are required. This may include prior treatment with investigational products.
• •Able to perform the activities of daily living.
• •Off prior therapy for at least 2-4 weeks depending on the drug.
• •Blood counts and blood chemistries in or near normal range.
• •If female, neither pregnant nor nursing.
• •Willing to use contraceptives to prevent pregnancy.
• •No other serious illnesses.
• •No other active malignancy.
• •No serious infections.
• •No current other drug therapy for the myeloma except for steroid therapy under certain circumstances. Biphosphonate therapy is permitted.
• •Prior radiation is permitted.